Sofinnova Investments

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Founded in 2012, Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area. It focuses on developing innovative therapeutics for rare and age-related diseases by targeting molecular pathways that address underlying causes of disease initiation and progression.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Aiolos Bio is a biotechnology company specializing in the development of therapies for respiratory diseases and immune conditions. Its primary focus is on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma, designed for dosing every 6 months. The company, founded by industry veterans, aims to address unmet treatment needs and improve patient outcomes by providing more efficacious and less burdensome therapies.

Star Therapeutics aims to develop therapies for numerous rare diseases by identifying those with shared biological pathways. This approach enables the creation of single treatments capable of addressing multiple conditions, thereby expanding pharmaceutical pipelines.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston that specializes in developing treatments for serious ophthalmic conditions. The company's primary focus is on addressing untreatable diseases of the eye, with its lead drug candidate being an orally delivered compound aimed at treating Stargardt disease and age-related macular degeneration. Through its innovative approach, Alkeus aims to empower medical professionals to manage symptoms of irreversible vision loss at an earlier stage in affected patients.

Quanta Therapeutics is a biotechnology company focused on developing novel cancer therapeutic candidates. It specializes in allosteric modulation to directly inhibit RAS-driven cancer types by restoring conformational control of active RAS signaling at the cell membrane.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

ArriVent is a biopharmaceutical company focused on developing innovative medicines to treat currently untreatable cancers. It aims to advance its lead candidate, furmonertinib, and other novel therapeutics like next-generation antibody-drug conjugates through clinical development and commercialization, initially targeting solid tumors.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Quanta Therapeutics is a biotechnology company focused on developing novel cancer therapeutic candidates. It specializes in allosteric modulation to directly inhibit RAS-driven cancer types by restoring conformational control of active RAS signaling at the cell membrane.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

Aerovate Therapeutics, founded in 2018 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to improving the lives of patients with rare cardiopulmonary diseases. Its primary focus is AV-101, an inhaled dry powder formulation of imatinib, designed to deliver medication directly to affected lung tissues while minimizing systemic side effects. This innovative approach aims to treat pulmonary arterial hypertension (PAH), a severe and progressive disease.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Bolt Biotherapeutics is a biotechnology company developing cancer immunotherapies based on the Boltbody platform, which links tumor-targeting antibodies to immune-stimulating payloads to activate innate and adaptive immune responses against solid tumors. The platform aims to transform non-responsive, or cold, tumors into immunologically active ones by delivering immune stimulants at the tumor site. The company’s pipeline includes BDC-1001 as a monotherapy for HER2-expressing solid tumors, with additional candidates such as BDC-3042 and Next-Gen ISAC designed to broaden its immuno-oncology program. Bolt Biotherapeutics focuses on myeloid biology and tumor-targeted therapies to leverage immune mechanisms for cancer treatment.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Akouos is a biotechnology company focused on precision genetic medicine to restore and preserve hearing. Based in Boston, it develops gene therapies using a proprietary adeno-associated viral vector platform and delivery approaches to treat sensorineural hearing loss in genetically defined populations. The company's lead program, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos pursues research and development across gene-based interventions aimed at improving auditory function and long-term sensory outcomes. It has collaborations with academic and industry partners, including Massachusetts Eye and Ear and Lonza, to advance discovery and manufacturing capabilities. Founded in 2016, Akouos addresses unmet clinical needs in auditory health by seeking to restore physiologic hearing through targeted genetic therapies.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.

Intrepida Bio, Inc. is a biotechnology company focused on developing innovative cancer therapies that enhance the body’s innate immune response. Founded in 2016 and headquartered in San Diego, California, the company specializes in creating medicines that modulate the innate immune system to combat cancer and other diseases. Intrepida Bio is particularly engaged in the development of monoclonal antibodies aimed at novel targets such as BAG3 and its receptor IFITM-2, which are involved in establishing a tumor-friendly environment. Through its research efforts, Intrepida Bio aims to provide patients with effective treatment options to fight cancer.

Founded in 2012, Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area. It focuses on developing innovative therapeutics for rare and age-related diseases by targeting molecular pathways that address underlying causes of disease initiation and progression.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapeutics for rare fibrotic diseases and retinal fibrovascular conditions. The company targets conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein designed for intravenous injection, and PRM-167, a variant formulated for intravitreal delivery. Promedior employs a novel drug discovery platform that aims to regulate monocyte-derived cell populations, which are critical in inflammatory, fibrotic, and autoimmune diseases. By specifically addressing these cells at the injury site, Promedior seeks to treat the underlying causes of immune system dysregulation, promote tissue healing, and minimize systemic side effects associated with traditional therapies. The company's commitment to addressing severe and challenging conditions positions it as a significant player in the biopharmaceutical landscape.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that focuses on discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate, NC318, is currently undergoing Phase 2 clinical trials for advanced or metastatic solid tumors. Additionally, NextCure is developing NC410, designed to inhibit immune suppression through the modulation of a specific immune receptor. The company is also advancing other product candidates, including LNCB74, an antibody-drug conjugate targeting B7-H4, and is exploring additional immunomodulatory molecules in preclinical stages. NextCure has established collaborations with Yale University for licensing and with Eli Lilly and Company for research and development. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets in its pursuit of first-in-class immunotherapy solutions.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

Akouos is a biotechnology company focused on precision genetic medicine to restore and preserve hearing. Based in Boston, it develops gene therapies using a proprietary adeno-associated viral vector platform and delivery approaches to treat sensorineural hearing loss in genetically defined populations. The company's lead program, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos pursues research and development across gene-based interventions aimed at improving auditory function and long-term sensory outcomes. It has collaborations with academic and industry partners, including Massachusetts Eye and Ear and Lonza, to advance discovery and manufacturing capabilities. Founded in 2016, Akouos addresses unmet clinical needs in auditory health by seeking to restore physiologic hearing through targeted genetic therapies.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Neurana Pharmaceuticals is a biotechnology company based in San Diego, California, focused on developing treatments for neuromuscular conditions. Founded in 2013, the company specializes in addressing acute and painful muscle spasms of the neck and back. Neurana's flagship therapeutic compound is Tolperisone, which treats musculoskeletal conditions such as neuromuscular spasms and spasticity without causing sedation. The company aims to provide fast relief for patients suffering from these conditions.

Merus is a clinical-stage immuno-oncology company focused on discovering and developing bispecific antibody therapeutics. It utilizes Oligoclonics technology to produce mixtures of human therapeutic antibodies directed to a common antigen from a single cell clone and develops full-length multispecific antibodies known as Biclonics. Merus' pipeline includes bispecific programmes such as MCLA-128, MCLA-117 and MCLA-158, reflecting its emphasis on targeted immune engagement in cancer.

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company has a diverse pipeline of clinical-stage product candidates, including Rilonacept, which is undergoing Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, currently in Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Kiniksa also has preclinical candidates, such as KPL-404, which targets the CD40/CD40L interaction in immune responses. Additionally, the company is collaborating with Kite Pharma to explore the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa Pharmaceuticals aims to address multiple autoimmune and autoinflammatory conditions through its innovative approaches.

Quanta Therapeutics is a biotechnology company focused on developing novel cancer therapeutic candidates. It specializes in allosteric modulation to directly inhibit RAS-driven cancer types by restoring conformational control of active RAS signaling at the cell membrane.

Pionyr Immunotherapeutics Inc. is a biotechnology company focused on developing innovative cancer immunotherapies that specifically target the tumor microenvironment to enhance the body's antitumor immunity. Founded in 2015 and based in San Francisco, California, Pionyr leverages advanced target discovery and antibody generation platform technologies to create next-generation immuno-oncology therapeutics. The company's proprietary approach, known as Myeloid Tuning™, aims to improve the immune system’s anti-tumor response by precisely altering the cellular composition within the tumor microenvironment. This strategy is designed to enable patients to better combat cancer, particularly when used in conjunction with checkpoint inhibitors.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative antibody-based therapies for cancer treatment in the United States. The company's lead product, DANYELZA, is an FDA-approved monoclonal antibody targeting ganglioside GD2, which is present in various neuroectoderm-derived tumors and sarcomas. Y-mAbs is advancing several other candidates, including naxitamab, currently in Phase 2 trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, and omburtamab, also in Phase 2 trials for desmoplastic small round cell tumors. Additionally, the company is developing a GD2-GD3 vaccine and exploring the huB7-H3 candidate for adult solid tumors. Y-mAbs collaborates with leading institutions, including Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, to enhance its antibody constructs using advanced therapeutic platforms. Founded in 2015 and headquartered in New York, Y-mAbs aims to provide novel treatments that may reduce the long-term toxicities associated with traditional chemotherapies while potentially offering curative options for patients with widespread disease.

Medeor Therapeutics, Inc. is a biotechnology company focused on researching, developing, and commercializing innovative cellular immunotherapies aimed at enhancing outcomes for organ transplant recipients. Based in San Mateo, California, Medeor Therapeutics has developed a specialized immunotherapy product for kidney transplant recipients known as MDR-10X. The company's cellular immunotherapies target organ transplant immune tolerance and immuno-oncology, providing healthcare providers with advanced techniques to preserve or improve kidney function and mitigate the risk of graft rejection more effectively than traditional immunosuppression therapies. Incorporated in 2012, Medeor Therapeutics is dedicated to transforming transplant outcomes through personalized treatment strategies.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Entasis Therapeutics is a biopharmaceutical company focused on developing novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria. Its pipeline includes ETX2514SUL for Acinetobacter baumannii infections, ETX0282CPDP for Enterobacteriaceae infections, and zoliflodacin for Neisseria gonorrhoeae.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing novel anti-infectives to combat multi-drug resistant pathogens. Its lead product, sulopenem, is a penem antibiotic with both oral and intravenous formulations, currently in Phase III trials for treating various urinary tract infections and intra-abdominal infections.

AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, focused on developing and manufacturing treatments for mucosal diseases. Established in 2014, the company is known for its flagship product, the Rivelin® patch, which is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver medication directly to the affected area. By offering targeted therapies for conditions that currently lack approved treatment options, AFYX Therapeutics aims to enhance patient relief and support recovery without disrupting daily activities.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Dauntless Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2015. It specializes in the development and manufacturing of specialty pharmaceutical drugs, particularly therapeutics for endocrine cancers. The company is known for its lead product, Dauntless 1, which targets endocrine cancers, and is also developing DP1038, another therapeutic agent for the same purpose. Dauntless Pharmaceuticals aims to provide innovative treatment options, including non-injectable alternatives to existing somatostatin analogs, which are commonly administered via injection for conditions such as acromegaly and neuroendocrine tumors. This focus on non-invasive therapies seeks to improve patient access and comfort in managing these conditions.

Ascendis Pharma is a biopharmaceutical company that uses its TransCon prodrug technology platform to create long-acting therapies across endocrinology and oncology. The company's TransCon growth hormone targets growth hormone deficiency in children and has completed Phase III development; TransCon PTH is in Phase II for hypoparathyroidism, and TransCon CNP is in Phase II for achondroplasia; it is pursuing preclinical oncology programs and evaluating systemic and localized delivery; the platform enables control of exposure via TransCon carrier and linker to determine dosing frequency, with prodrugs releasing the active drug in its native form. Ascendis collaborates with Sanofi to co-develop TransCon technologies for diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing novel anti-infectives to combat multi-drug resistant pathogens. Its lead product, sulopenem, is a penem antibiotic with both oral and intravenous formulations, currently in Phase III trials for treating various urinary tract infections and intra-abdominal infections.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that focuses on discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate, NC318, is currently undergoing Phase 2 clinical trials for advanced or metastatic solid tumors. Additionally, NextCure is developing NC410, designed to inhibit immune suppression through the modulation of a specific immune receptor. The company is also advancing other product candidates, including LNCB74, an antibody-drug conjugate targeting B7-H4, and is exploring additional immunomodulatory molecules in preclinical stages. NextCure has established collaborations with Yale University for licensing and with Eli Lilly and Company for research and development. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets in its pursuit of first-in-class immunotherapy solutions.

Dauntless Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2015. It specializes in the development and manufacturing of specialty pharmaceutical drugs, particularly therapeutics for endocrine cancers. The company is known for its lead product, Dauntless 1, which targets endocrine cancers, and is also developing DP1038, another therapeutic agent for the same purpose. Dauntless Pharmaceuticals aims to provide innovative treatment options, including non-injectable alternatives to existing somatostatin analogs, which are commonly administered via injection for conditions such as acromegaly and neuroendocrine tumors. This focus on non-invasive therapies seeks to improve patient access and comfort in managing these conditions.

First Aid Shot Therapy, founded in 2010 and headquartered in Burlingame, California, specializes in clinical beverages aimed at addressing acute and chronic health needs. The company offers a variety of easy-to-swallow, single-dose products that provide rapid relief for common everyday symptoms such as hangover, pain, sleep issues, cold, allergy, and heartburn. By focusing on fast-acting solutions, First Aid Shot Therapy aims to help consumers manage their symptoms quickly and conveniently.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Principia Biopharma Inc. is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead product, rilzabrutinib, is an inhibitor undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 trials for immune thrombocytopenia and Phase 2 trials for IgG4-related disease. Additionally, Principia is developing PRN2246/SAR442168, which is in Phase II for multiple sclerosis and other central nervous system conditions, alongside PRN473, a drug candidate in Phase I trials for immune-mediated diseases. Principia Biopharma maintains a collaboration agreement with Genzyme Corporation for the development of treatments for MS and other CNS diseases. Originally incorporated in 2008, the company is dedicated to addressing significant unmet medical needs in immunology and oncology through its innovative drug development platform.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Dauntless Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2015. It specializes in the development and manufacturing of specialty pharmaceutical drugs, particularly therapeutics for endocrine cancers. The company is known for its lead product, Dauntless 1, which targets endocrine cancers, and is also developing DP1038, another therapeutic agent for the same purpose. Dauntless Pharmaceuticals aims to provide innovative treatment options, including non-injectable alternatives to existing somatostatin analogs, which are commonly administered via injection for conditions such as acromegaly and neuroendocrine tumors. This focus on non-invasive therapies seeks to improve patient access and comfort in managing these conditions.

Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

Merus is a clinical-stage immuno-oncology company focused on discovering and developing bispecific antibody therapeutics. It utilizes Oligoclonics technology to produce mixtures of human therapeutic antibodies directed to a common antigen from a single cell clone and develops full-length multispecific antibodies known as Biclonics. Merus' pipeline includes bispecific programmes such as MCLA-128, MCLA-117 and MCLA-158, reflecting its emphasis on targeted immune engagement in cancer.

Edge Therapeutics is a clinical-stage biotechnology company based in Berkeley Heights, New Jersey, focused on developing innovative therapies for acute, life-threatening neurological conditions. Established in 2009, the company aims to transform treatment paradigms in hospital settings through its proprietary platform, Precisa, which facilitates the creation of polymer-based therapeutics designed for targeted delivery to injury sites. The lead product candidate, EG-1962, is currently undergoing evaluation in the Phase 3 NEWTON 2 study, aimed at improving outcomes for patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). Additionally, Edge is assessing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aimed at preventing recurrent bleeding on the brain's surface. Through these efforts, Edge Therapeutics seeks to address serious unmet medical needs in the field of neurology.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

aTyr Pharma is a biotherapeutics company focused on discovering and developing protein biologics for human therapeutics. Its primary program, ATYR1923, is a clinical-stage product candidate designed to modulate immune engagement in interstitial lung diseases.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing novel anti-infectives to combat multi-drug resistant pathogens. Its lead product, sulopenem, is a penem antibiotic with both oral and intravenous formulations, currently in Phase III trials for treating various urinary tract infections and intra-abdominal infections.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that focuses on discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate, NC318, is currently undergoing Phase 2 clinical trials for advanced or metastatic solid tumors. Additionally, NextCure is developing NC410, designed to inhibit immune suppression through the modulation of a specific immune receptor. The company is also advancing other product candidates, including LNCB74, an antibody-drug conjugate targeting B7-H4, and is exploring additional immunomodulatory molecules in preclinical stages. NextCure has established collaborations with Yale University for licensing and with Eli Lilly and Company for research and development. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets in its pursuit of first-in-class immunotherapy solutions.

Histogenics is a regenerative medicine company focused on developing and commercializing products for musculoskeletal conditions. Its platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to treat cartilage damage, with NeoCart® being its first investigational product candidate.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Ascendis Pharma is a biopharmaceutical company that uses its TransCon prodrug technology platform to create long-acting therapies across endocrinology and oncology. The company's TransCon growth hormone targets growth hormone deficiency in children and has completed Phase III development; TransCon PTH is in Phase II for hypoparathyroidism, and TransCon CNP is in Phase II for achondroplasia; it is pursuing preclinical oncology programs and evaluating systemic and localized delivery; the platform enables control of exposure via TransCon carrier and linker to determine dosing frequency, with prodrugs releasing the active drug in its native form. Ascendis collaborates with Sanofi to co-develop TransCon technologies for diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.